New drug combo aims to tackle Chemotherapy-Resistant colorectal cancer in the abdomen

NCT ID NCT05700656

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This trial investigates whether combining two drugs—galunisertib and capecitabine—can help people with advanced colorectal cancer that has spread to the lining of the abdomen (peritoneal metastases) and no longer responds to standard chemotherapy. The study has two parts: first, finding the safest dose, and then testing how well the combination works at shrinking tumors. It includes about 31 participants and measures safety, tumor response, and how long any benefit lasts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
galunisertib plus capecitabine
What this could lead to
If it works, this combination could offer a new treatment option for people with advanced colorectal cancer that has spread to the abdomen and has stopped responding to standard therapies.
What could go wrong
This is an early-phase trial with a small number of participants, so the results may not apply to everyone. The combination may cause side effects, and it is not yet known if it will effectively shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Amsterdam UMC

    Amsterdam, 1081 HV, Netherlands

  • Netherlands Cancer Institute

    Amsterdam, 1066CX, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.